FREMONT, Calif., Feb. 24, 2025 /PRNewswire/ — Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce the release of the ...

Jeff Borgia, Ph.D. is the Director of the Rush Cancer Center Biorepository, where he oversees the collection and annotation of patient specimens in support of ongoing translational research projects ...

Understand the importance of targeted assays in personalised medicine and how early decisions shape clinical outcomes.

In our best practices blog, we explore how lateral flow assay design affects test performance. Read on to gain a deeper understanding of the development process, enabling you to streamline the ...

As AI accelerates target discovery and pushes more candidates toward the bench, assay development and transfer have become critical bottlenecks. Teams relying on one-factor-at-a-time (OFAT) workflows ...

Optimizing PCR assays for assay development (AD) workflows typically involves a range of interdependent factors. These include thermocycling conditions, enzyme levels, buffer chemistry, and ...

The COVID-19 pandemic and geopolitical conflict in Eastern Europe have done irreparable damage to the underpinnings of the clinical diagnostic industry. These events significantly impacted the supply ...

Since biological therapeutics are derived from living organisms, their manufacture and validation presents difficulties not encountered during traditional small molecule drug development. Despite the ...

Discover advancements in assay development and cell-based screening models with insights on AI, high-throughput screening, and toxicity detection from ELRIG Drug Discovery posters in this eBook.

The Molecular Diagnostic and Assay Development Hub is focused on expanding our targeted and agnostic diagnostic capabilities against viral threats with pandemic potential. During the two-year start-up ...